--- title: "Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)" ocid: "ocds-h6vhtk-0595dd" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0595dd" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-0595dd.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-0595dd.json" source: "Find A Tender Service" current_stage: "Award" buyer: "NHS ENGLAND" published: "2026-01-16" --- # Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults) Buyer: NHS ENGLAND Current stage: Award OCID: ocds-h6vhtk-0595dd [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0595dd) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-0595dd.json) ## Summary This public procurement involves NHS England, represented by NHS Arden and Greater East Midlands Commissioning Support Unit, undertaking the process for commissioning Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adults with melanoma. The focus is on health services, with the process utilizing an open procedure under the Health Care Services (Provider Selection Regime) Regulations 2023. Contracts will be awarded across seven regions in England, including London, East of England, and North West, among others. Significant dates include a service commencement on 1st May 2025 and the contract duration lasting five years with an optional four-year extension. The notice to award is planned to be formalized according to NHS England governance, following the evaluation criteria focusing heavily on quality and innovation, along with integration, collaboration, and social value. The tender presents substantial opportunities for businesses specialising in healthcare and cell therapy, particularly those with expertise in melanoma treatment and cellular therapies like Lifileucel. This opportunity is geared towards established providers with necessary accreditations and licenses such as the Human Tissue Authority licence and Joint Accreditation Committee accreditations. By participating, businesses can significantly expand their service offerings across multiple high-value contracts, each possessing a lifetime value of approximately £11,876,000. This procurement not only targets the expansion of service provision across diverse geographic locations but also aims to tackle health inequalities, hence businesses with a focus on social value and innovation may find a particularly good fit. ## Notice NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). ### Lot Information Lot 1 - London NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London. The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). Lot 2 - East of England NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England. The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). Lot 3: South East NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East. The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). Lot 4: South West NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West. The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). Lot 5: Midlands NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands. The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). Lot 6: North East & Yorkshire NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire. The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). Lot 7: North West NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England: Lot 1: London Lot 2: East of England Lot 3: South East Lot 4: South West Lot 5: Midlands Lot 6: North East and Yorkshire Lot 7: North West This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned. As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West. The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years). Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s). ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/003869-2026 | | Notice type | Tender Notice | | Procurement type | Standard | | Procurement category | Services | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 16 Jan 2026 | | Submission deadline | 13 Oct 2025 | | Future notice date | Not specified | | Award date | 16 Dec 2025 | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £142,512,000 | | Lots value | £142,512,000 | | Awards value | Not specified | | Contracts value | £11,876,000 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Cancelled | | Awards status | Active | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Locality | LONDON | | Post town | South East London | | Postcode | SE1 8UG | | Country | England | | ITL 1 | TLI London | | ITL 2 | TLI4 Inner London - East | | ITL 3 | TLI45 Lambeth | | Local authority | Lambeth | | Electoral ward | Waterloo & South Bank | | Westminster constituency | Vauxhall and Camberwell Green | | Delivery location | TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England) | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 12 | | Supplier names | BARTS HEALTH NHS TRUST; CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST; GUY'S AND ST THOMAS' NHS FOUNDATION TRUST; OXFORD UNIVERSITY HOSPITALS NHS FT; THE CHRISTIE NHS FOUNDATION TRUST; THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST; THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST; THE ROYAL MARSDEN NHS FOUNDATION TRUST; UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST; UNIVERSITY HOSPITALS BRISTOL AND WESTON NHS FOUNDATION TRUST; UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST; UNIVERSITY HOSPITALS SOUTHAMPTON | ## CPV Codes ### Divisions - 85 - Health and social work services ### Codes - 85100000 - Health services ## Release History - 16 Jan 2026 at 12:42 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/003869-2026 - 8 Sep 2025 at 13:23 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/054675-2025 ## Notice URLs - https://health-family.force.com/s/Welcome - https://www.ardengemcsu.nhs.uk/ - https://www.england.nhs.uk/ - https://www.nice.org.uk/guidance/indevelopment/gid-ta10752 ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0595dd. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-0595dd.json.